GENETIC TECHNOLOGIES LIMITED — Board/Management Information 2008

Apr 22, 2008

==> picture [562 x 65] intentionally omitted <==

==> picture [562 x 66] intentionally omitted <==

ASX ANNOUNCEMENT

April 23[rd] , 2008

Management update

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce two key executive appointments to accelerate the Company’s transformation and implementation of its strategic agenda.

New management appointments:

• Ross Barrow has been appointed Chief Operating Officer. Mr. Barrow’s previous role was Director, Technology and Melbourne Operations for Leica Biosystems Division, a subsidiary of NYSE-listed Danaher Corporation. Ross was previously the Chief Operating Officer of Vision BioSystems Limited and, prior to that, spent 11 years with BHP in a variety of roles managing major R&D and technology development programs. Ross brings more than ten years of senior management experience in the clinical in-vitro diagnostics industry as well as broad experience in managing global teams and operations.

• Catherine Barclay has been appointed People and Customer Service Manager. Ms. Barclay was previously the Human Resources Operations Manager with AXA APH. She has more than eight years human resources experience and ten years experience managing customer service teams in the financial services sector.

Chief Executive Officer of Genetic Technologies Limited, Mr. Michael Ohanessian, said the new appointments are a critical step in the development and implementation of the Company’s strategic goals.

“These appointments are very important to the future of Genetic Technologies. We are extremely fortunate to have secured the services of such high calibre people with extensive business and international management expertise,” he said.

In other personnel changes, Genetic Technologies’ Chief Scientific Officer, Dr. Gary Cobon, has decided to leave the Company. “Gary leaves Genetic Technologies after having implemented new systems and processes that have greatly improved the functioning of our research and development projects and he does so with our best wishes for the future,” said Mr. Ohanessian.

---

FOR FURTHER INFORMATION PLEASE CONTACT

Michael B. Ohanessian Chief Executive Officer

Genetic Technologies Limited Phone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtg.com.au • Email : info@gtg.com.au ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040